ConductScience.org, home

Paper39199550

Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.

Rahman M and 7 others. Cancers (Basel), 2024. Cited by 14 papers, by iCite.

Cite this record

ConductScience Library. Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies. Papers, record 39199550. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39199550

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Synergistic Strategies for Castration-Resistant Prostate Cancer: Targeting AR-V7, Exploring Natural Compounds, and Optimizing FDA-Approved Therapies.
PubMed
Journal
Cancers (Basel)
PubMed
Year
2024
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
14
iCite
Relative citation ratio, by iCite
2.49, provisional
iCite
Revised in PubMed
2026-09-22
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Rahman MMuntajin
2Akter KKhadija
3Ahmed KRKazi Rejveehttps://orcid.org/0000-0002-6273-0645
4Fahim MMHMd Maharub Hossain
5Aktary NNahida
6Park MNMoon Nyeohttps://orcid.org/0000-0002-9276-3894
7Shin SWSang-Won
8Kim BBongleehttps://orcid.org/0000-0002-8678-156X

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

Grants4

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
NRF-2020R1I1A2066868Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of EducationPubMed
2020R1A5A2019413National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT)PubMed
RS-2020-KH087790Ministry of Health & Welfare, Republic of KoreaPubMed
RS-2024-00350362national Research Foundation of korea (NRF) grant funded by the korea Government (MSIT)PubMed

Source PubMed

Download CSV of grants

References217

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124278513Berberine inhibited radioresistant effects and enhanced anti-tumor effects in the irradiated-human prostate cancer cells.Toxicol Res2010https://conductscience.org/library/papers/24278513PubMed
238224119A bis-quinoline ruthenium(II) arene complex with submicromolar cytotoxicity in castration-resistant prostate cancer cells.Chem Commun (Camb)2024https://conductscience.org/library/papers/38224119PubMed
331801262Curcumin and Its Derivatives as Potential Therapeutic Agents in Prostate, Colon and Breast Cancers.Molecules2019https://conductscience.org/library/papers/31801262PubMed
425649018Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome.Clin Cancer Res2015https://conductscience.org/library/papers/25649018PubMed
516101488Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents2005https://conductscience.org/library/papers/16101488PubMed
637446908Epigallocatechin-3-Gallate Therapeutic Potential in Cancer: Mechanism of Action and Clinical Implications.Molecules2023https://conductscience.org/library/papers/37446908PubMed
718281560Honokiol, a constituent of oriental medicinal herb magnolia officinalis, inhibits growth of PC-3 xenografts in vivo in association with apoptosis induction.Clin Cancer Res2008https://conductscience.org/library/papers/18281560PubMed
832710433Mitoxantrone triggers immunogenic prostate cancer cell death via p53-dependent PERK expression.Cell Oncol (Dordr)2020https://conductscience.org/library/papers/32710433PubMed
939341127Nanodelivery system of traditional Chinese medicine bioactive compounds: Application in the treatment of prostate cancer.Phytomedicine2024https://conductscience.org/library/papers/39341127PubMed
1027499349Sulforaphane increases the efficacy of anti-androgens by rapidly decreasing androgen receptor levels in prostate cancer cells.Int J Oncol2016https://conductscience.org/library/papers/27499349PubMed
1129065980Genistein: Its role in metabolic diseases and cancer.Crit Rev Oncol Hematol2017https://conductscience.org/library/papers/29065980PubMed
1234354111Conformational dynamics of androgen receptors bound to agonists and antagonists.Sci Rep2021https://conductscience.org/library/papers/34354111PubMed
1326137992Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.Sci Rep2015https://conductscience.org/library/papers/26137992PubMed
1436172195Synergistic effects of natural products in combination with anticancer agents in prostate cancer: A scoping review.Front Pharmacol2022https://conductscience.org/library/papers/36172195PubMed
1517326044Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells.Cancer2007https://conductscience.org/library/papers/17326044PubMed
1625325026Honokiol, a constituent of Magnolia species, inhibits adrenergic contraction of human prostate strips and induces stromal cell death.Prostate Int2014https://conductscience.org/library/papers/25325026PubMed
1735829924Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends.Clin Drug Investig2022https://conductscience.org/library/papers/35829924PubMed
1820807808Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Cancer Res2010https://conductscience.org/library/papers/20807808PubMed
1919536890Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.Cancer2009https://conductscience.org/library/papers/19536890PubMed
2026912557Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study.Ann Oncol2016https://conductscience.org/library/papers/26912557PubMed

See all 217 referencesDownload CSV of references

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 14 citations.

PMIDTitleJournalYearIn PapersSource
42280440Herbal Neurotherapeutics for Cognitive Disorders: Integrative Mechanisms Linking Neurotransmitter Systems, Neurodegeneration, and the Gut-Brain Axis.Nutrients2026https://conductscience.org/library/papers/42280440PubMed
42047726Rewired lipid metabolism in castration-resistant prostate cancer: molecular interplay between glucose metabolism and sterol synthesis.Mol Biol Rep2026https://conductscience.org/library/papers/42047726PubMed
41827723Bioactive Natural Products Targeting Androgen Receptor Signaling in Prostate Cancer: A Systematic Review.Cancers (Basel)2026https://conductscience.org/library/papers/41827723PubMed
41827159Targeting VEGF, PARP, and FRα Pathways in Ovarian Cancer: Clinical Advances with Bevacizumab, Rucaparib, and Mirvetuximab Soravtansine.J Clin Med2026https://conductscience.org/library/papers/41827159PubMed
41598623
Emerging Therapeutic Strategies in Prostate Cancer: Targeted Approaches Using PARP Inhibition, PSMA-Directed Therapy, and Androgen Receptor Blockade with Olaparib, Lutetium (177Lu)Vipivotide Tetraxetan, and Abiraterone.
J Clin Med2026https://conductscience.org/library/papers/41598623PubMed
41596531Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?Int J Mol Sci2026https://conductscience.org/library/papers/41596531PubMed
41503910CD24 and Mutant p53: Emerging Therapeutic Targets in Prostate Cancer Progression.Anticancer Agents Med Chem2026https://conductscience.org/library/papers/41503910PubMed
41151861Verbascoside Suppresses Epithelial-Mesenchymal Transition and Mitochondrial Biogenesis by Targeting Anti-senescence Signaling in Castration-resistant Prostate Cancer.Cancer Genomics Proteomics2025https://conductscience.org/library/papers/41151861PubMed
41020838Revisiting Curcumin in Cancer Therapy: Recent Insights into Molecular Mechanisms, Nanoformulations, and Synergistic Combinations.Curr Issues Mol Biol2025https://conductscience.org/library/papers/41020838PubMed
40626308Unveiling the therapeutic potential of natural products in Alzheimer's disease: insights from in vitro, in vivo, and clinical studies.Front Pharmacol2025https://conductscience.org/library/papers/40626308PubMed
40498093Overcoming resistance mechanisms in cancer immunotherapy-novel approaches and combinations.Naunyn Schmiedebergs Arch Pharmacol2025https://conductscience.org/library/papers/40498093PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
AR367PubTator's text mininghttps://conductscience.org/library/genes/367

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39199550

GET https://conductscience.org/api/papers/v1/39199550/references?page=2